Get an alert when ORIBIOTECH LTD files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-07-23 (in 2mo)

Last made up 2025-07-09

Watchouts

1 item

Cash

£13M

-63.5% vs 2023

Net assets

£23M

-44.5% vs 2023

Employees

64

+8.5% vs 2023

Profit before tax

-£22M

-5.9% vs 2023

Watchouts

Facts from the Companies House register and the latest accounts — not a rating

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £106,000£474,000
Operating profit -£22,481,000-£23,229,000
Profit before tax -£20,946,000-£22,173,000
Net profit -£16,667,000-£19,330,000
Cash £35,148,000£12,833,000
Total assets less current liabilities
Net assets £41,843,000£23,222,000
Equity £41,843,000£23,222,000
Average employees 5964
Wages £6,056,000£6,763,000

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin -21208.5%-4900.6%
Net margin -15723.6%-4078.1%
Gearing (liabilities / total assets) 6.1%9.4%
Current ratio 15.94x9.27x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
IFRS
Reporting scope
Consolidated group
Auditor
RSM UK Audit LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The Directors have concluded that the Group is a going concern at the date of approval of these financial statements Further information can be found in note 1.2 of the financial statements.”

Group structure

  1. ORIBIOTECH LTD · parent
    1. Ori Biotech North America Inc 1% · USA · cell and gene therapy manufacturing platform distributor

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

5 active · 9 resigned

Name Role Appointed Born Nationality
FOSTER, Jason Charles Director 2019-07-29 Dec 1974 American
HAY, Jonathan Russell Director 2020-08-21 Sep 1961 British,American
JACKSON, Andrea Liapis Director 2024-02-01 Aug 1978 American
JENKINS, Annalisa Mary, Dr Director 2021-06-30 Jun 1965 British
MEISTER, Paul Matthew Director 2021-12-23 Oct 1952 American
Show 9 resigned officers
Name Role Appointed Resigned
BARGE, Alan John, Dr Director 2019-07-29 2020-08-21
CLARE, Barry Director 2019-07-29 2026-01-09
KEDAR, Sharon Director 2020-08-21 2020-09-22
MASON, Christopher, Professor Director 2019-07-29 2026-01-09
MASON, Christopher Director 2015-09-02 2018-01-15
SOCHA, Pierre Robert Director 2019-07-29 2021-12-23
TRACEY, William Patrick Director 2018-03-26 2020-08-21
VERAITCH, Farlan Singh Director 2015-09-02 2026-01-09
WIESCHHAUS, Adam Joseph Director 2020-09-22 2024-02-01

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Mr Farlan Singh Veraitch Individual Shares 25–50% 2016-09-01 Ceased 2019-08-20

Filing timeline

Last 20 of 103 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2026-01-15 MA Memorandum articles
  • 2026-01-15 RESOLUTIONS Resolution
  • 2025-11-21 RESOLUTIONS Resolution
  • 2025-02-18 RESOLUTIONS Resolution
Date Type Category Description
2026-03-12 SH01 capital Capital allotment shares PDF
2026-01-30 SH10 capital Capital variation of rights attached to shares
2026-01-30 SH08 capital Capital name of class of shares
2026-01-16 TM01 officers Termination director company with name termination date PDF
2026-01-16 TM01 officers Termination director company with name termination date PDF
2026-01-16 TM01 officers Termination director company with name termination date PDF
2026-01-15 MA incorporation Memorandum articles
2026-01-15 RESOLUTIONS resolution Resolution
2025-11-21 RESOLUTIONS resolution Resolution
2025-11-20 MR01 mortgage Mortgage create with deed with charge number charge creation date PDF
2025-09-05 AD01 address Change registered office address company with date old address new address PDF
2025-07-29 CS01 confirmation-statement Confirmation statement with updates PDF
2025-07-29 SH01 capital Capital allotment shares PDF
2025-07-29 SH01 capital Capital allotment shares PDF
2025-07-24 AA accounts Accounts with accounts type group
2025-06-16 MR04 mortgage Mortgage satisfy charge full PDF
2025-02-18 RESOLUTIONS resolution Resolution
2024-12-05 MR01 mortgage Mortgage create with deed with charge number charge creation date PDF
2024-07-25 CS01 confirmation-statement Confirmation statement with updates PDF
2024-07-25 SH01 capital Capital allotment shares PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
16

last 12 months

Capital events
6

last 24 months

Officers appointed
0

last 12 months

Officers resigned
3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page